John French trained in molecular medicine and oxygen radical biochemistry in Christchurch, Adelaide and London (where he undertook a Wellcome Trust funded post doc in Molecular Medicine). His clinical training was largely in Auckland (NZ), where he was consultant cardiologist at Green Lane Hospital from 1992-2003, though he continued molecular genetic research in hypertrophic cardiomyopathy, and established a genetic cardiology clinic.
John French trained in molecular medicine and oxygen radical biochemistry in Christchurch, Adelaide and London (where he undertook a Wellcome Trust funded post doc in Molecular Medicine). His clinical training was largely in Auckland (NZ), where he was consultant cardiologist at Green Lane Hospital from 1992-2003, though he continued molecular genetic research in hypertrophic cardiomyopathy, and established a genetic cardiology clinic. Since January 2004 John French has been Director of Cardiac Research at St Liverpool Hospital NSW. Though retired from clinical work in September 2025, he has remained an HMO. He has also been a VMO at Wagga Wagga (WW) Base Hospital since 2004. and has undertaken private practice in WW and SW Sydney. A monthly cardiac genetics clinic with clinical geneticists was run for 20 years.
For the last 30+ years John French has been mainly a clinical trialist and outcomes researcher. A significant career highlight was the paper publication on emergency informed consent in ST-elevation myocardial infarction in the Lancet in 2003 showing that while consent processes may meet regulatory requirements, patient comprehension and competence to consent was not optimal. He presented at cardiovascular grand rounds at the Mayo Clinic, Rochester Minnesota. He has co-authored >270 peer-reviewed papers. John French’s current clinical research interests include cardiac biomarkers particularly high sensitivity troponins, treatments of ST-elevation myocardial infarction (he was National Leader of the STREAM-2 Trial [published 2023] and was a co-author of the 2016 Australian ACS guidelines (lead STEMI section). He chaired the clinical endpoints committees (CEC) of HERO-1, HERO-2 RAPID T, and PARTY trials and served on the CECs of PLATO, APEX-AMI and CANVAS trials. John French was PI of the rescue PCI (RAFT) trial. He has recently been national leader of the STREAM-2 and OYDSSEY trials
